---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-037414"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:38:44.816214+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech raises ~$6.8M via warrant exercise inducement, issues new Series G warrants

## Summary
- Entered inducement letters with holders of Series C/D/F warrants to exercise at $6.63 or $6.3219 per share.
- Company expects aggregate gross proceeds of up to ~$6.8M from the warrant exercises.
- In exchange, issues new Series G warrants to purchase up to 2,610,823 shares (250% of exercised shares) at $6.63, exercisable upon shareholder approval, 5-year term.
- New warrants include anti-dilution price reset with a floor of $1.326 per share and cashless exercise feature.
- Company to file resale registration statement for Series G warrant shares by Jan 8, 2026, seek SEC effectiveness by Feb 9, 2026.

## SEC filing metadata
- accession: 0001437749-25-037414
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/0001437749-25-037414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/mbrx20251210_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-037414
- JSON: https://secwatch.observer/filing/0001437749-25-037414.json
- Plain text: https://secwatch.observer/filing/0001437749-25-037414.txt

## Key facts
- Equity Issuances
  Moleculin Biotech, Inc. issued 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823 of warrant to holders of existing Series C warrants, Series D warrants and Series F warrants for aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants.
  - Security: warrant
  - Shares: 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823
  - Purchaser: holders of existing Series C warrants, Series D warrants and Series F warrants
  - Consideration: aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants
  source text: registration statements on Form S-1 (File No. 333-286276) and Form S-3 (File No. 333-290418). The Company anticipates receiving aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants before deducting fees and other expenses payable by it. Each Inducement Warrant has an exercise price of $6.63 per share, will be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/0001437749-25-037414-index.htm
- Material Agreements
  Moleculin Biotech, Inc. entered into Inducement Letters with holders of existing Series C, Series D, and Series F warrants valued at up to approximately $6.8 million (effective 2025-12-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: holders of existing Series C, Series D, and Series F warrants
  - Value: up to approximately $6.8 million
  - Effective: 2025-12-09
  source text: On December 9, 2025, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with: (i) the holder of existing Series C warrants and Series D warrants to purchase an aggregate of up to 727,969 shares of Company common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/0001437749-25-037414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.